CJC-1295 with DAC 5 mg
research-grade
lyophilized peptide powder
supplied in a glass vial. CJC-1295 with DAC is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH),
incorporating Drug Affinity Complex (DAC) technology to enable covalent binding to serum albumin and extend
circulating half-life in experimental models of GH/IGF-1 axis regulation.
Research Use Only:
All products are intended exclusively for laboratory and scientific research. Not for human or veterinary use.
Purity
High-purity research grade
Form
Lyophilized peptide powder
Content
5 mg CJC-1295 with DAC per vial
Packaging
Glass vial with sterile closure
Storage
Store lyophilized at 2–8 °C (desiccated, protect from light)
Molecular formula
C165H269N47O46
Molecular weight
~3647.1 g·mol⁻¹
Sequence / structure
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(Maleimidopropionyl)-NH2
CAS number
863288-34-0 (Base Peptide)
Tests
CJC-1295 with DAC test
In laboratory workflows, lyophilized research peptides are typically handled with suitable sterile diluents such as bacteriostatic water (BAC).
For a compatible research-only solvent, see
Bacteriostatic water – 10 ml
.
Research Overview
CJC-1295 with DAC is a long-acting GHRH analog based on the first 29 amino acids of human Growth Hormone-Releasing Hormone (Modified GRF 1-29),
further modified with a maleimidopropionyl Drug Affinity Complex (DAC) linked via lysine. In experimental in vitro and in vivo systems, this
design enables covalent binding to circulating albumin, markedly prolonging half-life and allowing sustained stimulation of GHRH receptors,
growth hormone (GH) secretion and downstream insulin-like growth factor 1 (IGF-1) signaling under controlled laboratory conditions.
Primary Research Areas
-
Sustained GH release:
used in models examining prolonged pituitary growth hormone output following extended GHRH receptor stimulation and albumin binding–mediated
half-life extension.
-
IGF-1 axis modulation:
applied in research exploring long-term elevations in circulating IGF-1, somatotropic axis activity and associated metabolic endpoints in
preclinical settings.
-
Extended GHRH receptor agonism:
used to study receptor occupancy, downstream cAMP/PKA signaling and desensitization or adaptation phenomena during chronic GHRH analog exposure.
-
Metabolism and body composition models:
incorporated into experimental designs evaluating how prolonged GH/IGF-1 elevation influences body composition, tissue remodeling and energy
metabolism markers in animals and other laboratory systems.
-
Pharmacokinetics of long-acting peptides:
used as a model compound in studies on albumin-binding peptide drugs, half-life extension strategies and modified-release endocrine analogs.
